Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Humira Gets EU Approval for Crohn's Disease | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Humira Gets EU Approval for Crohn’s Disease

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott received marketing authorization from the European Commission for the use of Humira as a treatment for severe Crohn’s disease. Humira is the first self-administered biologic for the treatment of Crohn’s disease, offering a convenient treatment option that can help patients control of their disease. This is the fourth indication for Humira in the U.S. and the EU.

Crohn’s disease is a chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more than one million people in North America and Europe. Common symptoms of Crohn’s disease include diarrhea, cramping, abdominal pain, weight loss, fever, and in some cases, rectal bleeding. Complications include intestinal obstruction, ulcers that form tunnels to surrounding tissues, and malnutrition.  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters